Shares of mRNA cancer vaccine-related companies are trading higher amid sympathy with Merck and Moderna after they announced that intismeran autogene with KEYTRUDA yielded recurrence-free survival in patients with completely resected stage IIB-IV melanoma.

Head and Neck Squamous Cell Carcinoma (HNSCC) - Market Insights, Epidemiology, and Market Forecast - 2036 | Set to Reach $2.56 Billion as HPV-Targeted Vaccines Reshape Care

The HNSCC market is projected to grow from $850 million in 2025 to $2.56 billion by 2036 (10.5% CAGR), driven by HPV-targeted vaccines, checkpoint inhibitors, and biomarker-led patient selection. The US will remain the largest market at $2.082 billion. Key therapies include KEYTRUDA and OPDIVO, with emerging candidates like petosemtamab and amivantamab showing promise in clinical development.

Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Invivyd reported Phase 3 LIBERTY trial data for VYD2311, showing strong safety and enhanced COVID-19 antibody levels.

Reported Earlier: 'BioNTech to shutter three sites in Germany as no buyers emerge' - Reuters

https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-shutter-sites-germany-singapore-no-buyers-emerge-2026-09-28/

Why Is BioNTech Stock Gaining Monday?

BioNTech (BNTX) Phase 3 data reveals gotistobart almost doubles survival in advanced lung cancer over standard docetaxel.

ImmunityBio Stock Jumps: What's Going On?

ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.

China National Intellectual Property Administration Awards Maravai LifeSciences's TriLink BioTechnologies Patent Number ZL202511246658.5., Named "Compositions and Methods for Synthesizing 5'-Capped RNAs."